The simple version

The figure on the label is a starting number. It is the amount the maker starts from, before anything comes out of it.

Out of that number comes money that goes back to the plans and programs that cover the medicine, and to the firms that handle it on the way. What is left is what the maker keeps.

Those two numbers do not have to move together. The label figure can hold perfectly still while the money going back shrinks, and the maker keeps more without asking anyone for more.

The numbers

• Pfizer Inc. reported third-quarter 2026 revenues of $16.6 billion, stated as $16,583 million, in a release dated Tuesday, November 3, 2026.
• Under the heading QUARTERLY FINANCIAL HIGHLIGHTS (Third-Quarter 2026 vs. Third-Quarter 2025), after the line "Third-quarter 2026 operational revenue reflected higher revenues primarily for:", the release lists Eliquis global revenues up $513 million, or 25%, operationally.
• The release gives the reason for that rise as "driven primarily by higher net price in the U.S. primarily due to pricing dynamics, including lower rebates and channel mix favorability, as well as higher demand globally". The phrase "lower rebates" appears once in the release, in this bullet.
• The same bullet records offsetting falls "due to generic entry and price erosion in certain international markets".
• The figure is labeled operational by the release. We did not read the release's own definition of that term and do not restate the rise as reported growth.
• Pfizer's Form 10-Q for the quarter ended March 29, 2026 names what comes out of gross revenues under the heading Deductions from Revenues: Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances, sales returns and cash discounts.

Why the label figure is only the starting point

The label figure answers a question about what is asked. It is set by the maker and it is the same number for everyone who looks it up.

What the maker keeps answers a different question, about what is left once the money going back has gone. Those amounts are fixed one plan and one program at a time, so the sum kept varies by who is covering the medicine.

Because the two answer different questions, either one can move while the other does not. A quarter in which those amounts fall shows up as more money kept, with the label figure untouched and nobody paying more at the counter for that reason.

Running it the other way matters just as much. Larger amounts going back cut what the maker keeps while the label figure stays where it was, and the filing that reports the quarter is the only place the difference shows.

The actual math on a $100 medicine

Take a medicine with a label figure of $100 and two amounts going back, both ours rather than any document's. Say $40 goes back to a plan and $5 to a government program.

The maker keeps $55. Now hold the label figure at $100 and let the plan share fall to $30 while the government share stays at $5.

The maker now keeps $65, which is about 18 percent more than before, and the label figure never changed. The $100, the $40, the $30 and the $5 are all ours, and neither document we read gives such amounts for any medicine.

What this means

A headline about a medicine getting more expensive and a filing about a maker keeping more are not the same claim. One is about the label figure and the other is about what is left after the money going back.

It also means that none of this describes what a particular person hands over at the counter. That amount is set by the terms of their own coverage, which is a separate question this article does not answer.

The transferable habit is to ask whether a reported number is gross or net before comparing it with anything. Two numbers that share a name and differ by a round of money going back will tell opposite stories about the same quarter.

What this is NOT

This article explains what net price means for a medicine maker and why it can move apart from the figure on the label, using Pfizer Inc.'s third-quarter 2026 results release dated November 3, 2026 and its Form 10-Q for the quarter ended March 29, 2026, both read on November 3, 2026, as the worked example. The $100 medicine and every amount going back in the math section are ours, and neither filing we read gives such amounts for any medicine. It is not a recommendation to buy, sell or hold any security, and not a view on any company. It is not advice about any medicine, any treatment or any coverage choice, and it does not say what anyone will pay at a pharmacy counter, which depends on the terms of their own plan. It takes no position on whether medicine prices, rebates or any program is set correctly, and it does not forecast prices, revenues or policy. This is not a political endorsement or criticism of anyone.

Sources

• Pfizer Inc., Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance, release dated Tuesday, November 3, 2026: third-quarter revenues of $16,583 million, the Eliquis bullet under QUARTERLY FINANCIAL HIGHLIGHTS giving the increase of $513 million or 25% operationally and the net price language, and the offsetting generic entry and price erosion language. Read November 3, 2026: https://s206.q4cdn.com/795948973/files/content_files/Q3-2026-PFE-Earnings-Release-FINAL.pdf
• Pfizer Inc., Form 10-Q for the quarterly period ended March 29, 2026: the Deductions from Revenues heading and the categories taken out of gross revenues. Read November 3, 2026: https://s206.q4cdn.com/795948973/files/doc_financials/2026/q1/Form-10Q.pdf